Ten years of experience with weekly chemotherapy in metastatic breast cancer patients: Multivariate analysis of prognostic factors

Anti-Cancer Drugs

Volumn 17, Issue 10, 2006, Pages 1193-1200

  Nisticò, Cecilia ^a   Cuppone, Federica ^a   Bria, Emilio ^a   Fornier, Monica ^b   Giannarelli, Diana ^a   Mottolese, Marcella ^a   Novelli, Flavia ^a   Natoli, Guido ^a   Cognetti, Francesco ^a   Terzoli, Edmondo ^a  

^a REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Metastatic breast cancer; Prognostic factors; Weekly chemotherapy

Indexed keywords

ANTHRACYCLINE; EPIRUBICIN; LONIDAMINE; NAVELBINE; PACLITAXEL;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG ACTIVITY; DRUG TOLERABILITY; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; METASTASIS; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL; PROGNOSIS; PROPORTIONAL HAZARDS MODEL;

ADOLESCENT; ADULT; AGED; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CARCINOMA; CLINICAL TRIALS, PHASE II; DISEASE PROGRESSION; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM METASTASIS; PROGNOSIS; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 33750552338     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.cad.0000231485.17063.d3     Document Type: Article

References (38)

1. Jemal A, Thomas A, Murray T, Thun M. Cancer statistics. CA Cancer J Clin 2002; 52:23-47.
2. Beahrs OH, Henson DE, Hutter RVP. Manual for staging of cancer. 4th ed. Philadelphia: Lippincott; 1992.
3. Fossati R, Confalonieri C, Torri V, Ghislandi E, Penna A, Pistotti V, et al. Cytotoxic and hormonal treatment for metastatic breast cancer: a systematic review of published randomized trials involving 31,510 women. J Clin Oncol 1998; 1:3439-3460.
4. Bria E, Giannarelli D, Felici A, Peters WP, Nisticò C, Vanni B, et al. Taxanes with anthracyclines as first line chemotherapy for metastatic breast cancer: pooled analysis of 2805 patients. Cancer 2005; 103:672-679.
5. Albain KS, Nag S, Calderillo-Ruiz G, Jordaan JP, Llombart A, Pluzanska A, et al. Global phase III study of gemcitabine plus paclitaxel (GT) vs. paclitaxel (T) as frontline therapy for metastatic breast cancer (MBC): first report of overall survival. Proc Am Soc Clin Oncol 2004; 23: abstr 510.
6. O'Shaughnessy J, Miles D, Vukelja S, Moiseyenko V, Ayoub JP, Cervantes G, et al. Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results. J Clin Oncol 2002; 20:2812-2823.
7. Norton L. Conceptual and practical implications of breast tissue geometry: toward a more effective, less toxic therapy. Oncologist 2005; 10:370-381.
8. Seidman A. 'Will weekly work?' Seems to be so. J Clin Oncol 2005; 23:5873-5874.
9. Bonadonna G, Valagussa P. Dose-response effect of adjuvant chemotherapy in breast cancer. N Engl J Med 1981; 1:10-15.
10. Bonadonna G, Zambetti M, Valagussa P. Sequential or alternating doxorubicin and CMF regimens in breast cancer with more than three positive nodes. Ten-year results. JAMA 1995; 273:542-547.
11. Citron ML, Berry DA, Cirrincione C, Hudis C, Winer EP, Gradishar WJ, et al. Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of intergroup trial c9741/Cancer and Leukemia Group B trial 9741. J Clin Oncol 2003; 21:1431-1439.
12. Seidman AD, Berry D, Cirrincione L, Harris L, Dressler L, Muss H, et al. CALGB 9840: phase III study of weekly paclitaxel via 1-hour infusion versus standard 3-hour infusion every third week in the treatment of metastatic breast cancer (MBC), with trastuzumab (T) for HER2 positive MBC and randomized for T in HER2 normal MBC. J Clin Oncol 2004; 22:145 (abstr 512).
13. Green MC, Buzdar AU, Smith T, Nuhad KI, Valero V, Rosales MF, et al. Weekly paclitaxel improves pathologic complete remission in operable breast cancer when compared with once-every-3-weeks paclitaxel. J Clin Oncol 2005; 23:5983-5992.
14. Chung CT, Carlson RW. Goals and objectives in the management of metastatic breast cancer. Oncologist 2003; 8:514-520.
15. Miller AB, Hoogstraten B, Staquet M, Winkler A. Reporting results of cancer treatment. Cancer 1981; 47:207-214.
16. Botti C, Buglioni S, Benevolo M, Giannarelli D, Papaldo P, Cognetti F, et al. Altered expression of FAS system is related to adverse clinical outcome in stage I-II breast cancer patients treated with adjuvant anthracycline-based chemotherapy. Clin Cancer Res 2004; 10:1360-1365.
17. Nakamura Y, Yasuoka H, Tsujimoto M, Imabun S, Nakahara M, Nakao K, et al. Lymph vessel density correlates with nodal status, VEGF-C expression, and prognosis in breast cancer. Breast Cancer Res Treat 2005; 91:125-132.
18. Simon S. Optimal two-stage design for phase II clinical trials. Controlled Clin Trials 1989; 10:1-10.
19. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958; 53:475-481.
20. Nisticò C, Garufi C, Milella M, D'Ottavio AM, Vaccaro A, Fabi A, et al.Weekly epirubicin plus lonidamine in advanced breast carcinoma. Breast Canc Res Treat 1999; 1418:1-5.
21. Nisticò C, Garufi C, Barni S, Frontini L, Gallà D, Giannarelli D, et al. Phase II study of epirubicin and vinorelbine with granulocyte colony-stimulating factor: a high-activity, dose-dense weekly regimen for advanced breast cancer. Ann Oncol 1999; 10:937-942.
22. Nisticò C, Bria E, Vanni B, Tropea F, Izzo F, Aschelter AM, et al. Weekly epirubicin-paclitaxel as first line chemotherapy in advanced breast cancer patients: a phase II study. Proc Am Soc Clin Oncol 2003; 22:359 (abstr 280).
23. Giordano SH, Buzdar AU, Smith TL, Kau SW, Yang Y, Hortobagyi GN. Is breast cancer survival improving? Cancer 2004; 1:44-52.
24. Andre F, Slimane K, Bachelot T, Dunant A, Namer A, Barrelier A, et al. Breast cancer with synchronous metastases: trends in survival during a 14-year period. J Clin Oncol 2004; 22:3302-3308.
25. Marchetti P, Urien S, Antonini Cappellini G, Ronzino G, Ficorella C. Weekly administration of paclitaxel: theoretical and clinical basis. Crit Rev Oncol Hemat 2002; 44:S3-S13.
26. Taghian AG, Abi-Raad R, Assaad SI, Casty A, Ancukiewicz M, Yeh E, et al. Paclitaxel decreases the interstitial fluid pressure and improves oxygenation in breast cancers in patients treated with Neoadjuvant chemotherapy: clinical implications. J Clin Oncol 2005; 23:1951-1961.
27. Pasquier E, Honore S, Pourroy B, Jordan MA, Lehmann M, Briand C, et al. Anti-angiogenic concentrations of paclitaxel induce an increase in microtubule dynamics in endothelial cells but not in cancer cells. Cancer Res 2005; 65:2433-2440.
28. Nisticò C, Cognetti F, Frontini L, Barni S, Ferretti G, Bria E, et al. Weekly docetaxel in pretreated metastatic breast cancer patients: a phase I-II study. Oncology 2005; 68:356-363.
29. Piccart-Gebhart MJ. Mathematics and oncology: a match for life? J Clin Oncol 2003; 21:1425-1428.
30. Seidman AD. Single-agent paclitaxel in the treatment of breast cancer: phase I and II development. Semin Oncol 1999; 26(Suppl 8):14-20.
31. Konishi K, Tani Y, Minami S, Tamura M, Kameda H, Ogita M. Pharmacokinetic comparison between weekly paclitaxel treatment and by 3 weeks treatment in patients with metastatic breast cancer. Proc Am Soc Clin Oncol 2000; 21:abstr 2001.
32. Papaldo P, Lopez P, Marolla P, Cortesi E, Antimi A, Terzoli E, et al. Impact of five prophylactic Filgrastim schedules on hematologic toxicity in early breast cancer patients treated with epirubicin and cyclophosphamide. J Clin Oncol 2005; 23:6908-6918.
33. Nistico C, Garufi C, Barni S, Frontini L, Galla D, Giannarelli D, et al. Phase II study of epirubicin and vinorelbine with granulocyte colony-stimulating factor: a high-activity, dose-dense weekly regimen for advanced breast cancer. Ann Oncol 1999; 10:937-942.
34. Gennari A, Conte PF, Rosso R, Orlandini C, Bruzzi P. Survival of metastatic breast carcinoma patients over a 20-year period. A retrospective analysis based on individual patient data from six consecutive studies. Cancer 2005; 104:1742-1750.
35. Buyse M, Thirion P, Carlson RW, Burzykowski T, Molenberghs G, Piedbois P. Relation between tumour response to first-line chemotherapy and survival in advanced colorectal cancer: a meta-analysis. Lancet 2000; 356:373-378.
36. Greenberg PAC, Hortobagyi GN, Smith TL, Ziegler LD, Frye DK, Buzdar AU. Long-term follow-up of patients with complete remission following combination chemotherapy for metastatic breast cancer. J Clin Oncol 1996; 14:2197-2205.
37. Bruzzi P, Del Mastro L, Sormani MP, Bastholt L, Danova M, Focan C, et al. Objective response to chemotherapy as a potential surrogate end-point of survival in metastatic breast cancer patients. J Clin Oncol 2005; 23:5117-5125.
38. Di Leo A, Bleiberg H. Overall survival is not a realistic end-point for clinical trials of new drugs in advanced solid tumors: a critical assessment based on recently reported phase III trials in colorectal and breast cancer. J Clin Oncol 2003; 21:2045-2047.